WO2009009740A1 - Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation - Google Patents

Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation Download PDF

Info

Publication number
WO2009009740A1
WO2009009740A1 PCT/US2008/069813 US2008069813W WO2009009740A1 WO 2009009740 A1 WO2009009740 A1 WO 2009009740A1 US 2008069813 W US2008069813 W US 2008069813W WO 2009009740 A1 WO2009009740 A1 WO 2009009740A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
ccr2
substituted
unsubstituted
salt
Prior art date
Application number
PCT/US2008/069813
Other languages
English (en)
French (fr)
Inventor
Antoni Krasinski
Sreenivas Punna
Solomon Ungashe
Qiang Wang
Yibin Zeng
Original Assignee
Chemocentryx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2010516274A priority Critical patent/JP5306344B2/ja
Priority to KR1020167010696A priority patent/KR101790908B1/ko
Application filed by Chemocentryx, Inc. filed Critical Chemocentryx, Inc.
Priority to CN2008801077713A priority patent/CN101820881B/zh
Priority to ES08781709T priority patent/ES2383568T3/es
Priority to BRPI0813695A priority patent/BRPI0813695B8/pt
Priority to AU2008275000A priority patent/AU2008275000B2/en
Priority to KR1020187010175A priority patent/KR101969689B1/ko
Priority to PL08781709T priority patent/PL2175859T3/pl
Priority to KR1020177030097A priority patent/KR101849560B1/ko
Priority to AT08781709T priority patent/ATE548039T1/de
Priority to DK08781709.4T priority patent/DK2175859T3/da
Priority to CA2692761A priority patent/CA2692761C/en
Priority to EP08781709A priority patent/EP2175859B1/en
Publication of WO2009009740A1 publication Critical patent/WO2009009740A1/en
Priority to IL203258A priority patent/IL203258A/en
Priority to HK10109155.0A priority patent/HK1142547A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
PCT/US2008/069813 2007-07-12 2008-07-11 Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation WO2009009740A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
KR1020177030097A KR101849560B1 (ko) 2007-07-12 2008-07-11 염증의 치료를 위한 ｃｃｒ2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드
PL08781709T PL2175859T3 (pl) 2007-07-12 2008-07-11 Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia
CN2008801077713A CN101820881B (zh) 2007-07-12 2008-07-11 作为ccr2调节剂用于治疗炎症的稠合杂芳基吡啶基和苯基苯磺酰胺
KR1020167010696A KR101790908B1 (ko) 2007-07-12 2008-07-11 염증의 치료를 위한 ｃｃｒ2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드
BRPI0813695A BRPI0813695B8 (pt) 2007-07-12 2008-07-11 compostos de heteroaril piridil e fenil benzenossulfonamidas fundidas, composição, método de modular a função de ccr2, usos dos compostos e forma cristalina
AU2008275000A AU2008275000B2 (en) 2007-07-12 2008-07-11 Fused heteroaryl pyridyl and phenyl benzenesulfonamides as CCR2 modulators for the treatment of inflammation
AT08781709T ATE548039T1 (de) 2007-07-12 2008-07-11 Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
JP2010516274A JP5306344B2 (ja) 2007-07-12 2008-07-11 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド
ES08781709T ES2383568T3 (es) 2007-07-12 2008-07-11 Heteroaril piridil y fenil bencenosulfonamidas condensadas como moduladores de CCR2 para el tratamiento de la inflamación
KR1020187010175A KR101969689B1 (ko) 2007-07-12 2008-07-11 염증의 치료를 위한 ｃｃｒ2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드
DK08781709.4T DK2175859T3 (da) 2007-07-12 2008-07-11 Kondenserede heteroarylpyridyl- og phenylbenzen-sulfonamider som ccr2-modulatorer til behandling af inflammation
CA2692761A CA2692761C (en) 2007-07-12 2008-07-11 Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
EP08781709A EP2175859B1 (en) 2007-07-12 2008-07-11 Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
IL203258A IL203258A (en) 2007-07-12 2010-01-12 Terroyl pyridyl and phenyl benzencephalonamides, containing pharmaceuticals and their use in the treatment of conditions or diseases mediating 2ccr
HK10109155.0A HK1142547A1 (en) 2007-07-12 2010-09-24 Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94932807P 2007-07-12 2007-07-12
US60/949,328 2007-07-12

Publications (1)

Publication Number Publication Date
WO2009009740A1 true WO2009009740A1 (en) 2009-01-15

Family

ID=39852363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/069813 WO2009009740A1 (en) 2007-07-12 2008-07-11 Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation

Country Status (17)

Country Link
US (6) US7884110B2 (US20090233946A1-20090917-C00069.png)
EP (1) EP2175859B1 (US20090233946A1-20090917-C00069.png)
JP (1) JP5306344B2 (US20090233946A1-20090917-C00069.png)
KR (4) KR101790908B1 (US20090233946A1-20090917-C00069.png)
CN (1) CN101820881B (US20090233946A1-20090917-C00069.png)
AT (1) ATE548039T1 (US20090233946A1-20090917-C00069.png)
AU (1) AU2008275000B2 (US20090233946A1-20090917-C00069.png)
BR (1) BRPI0813695B8 (US20090233946A1-20090917-C00069.png)
CA (1) CA2692761C (US20090233946A1-20090917-C00069.png)
DK (1) DK2175859T3 (US20090233946A1-20090917-C00069.png)
ES (1) ES2383568T3 (US20090233946A1-20090917-C00069.png)
HK (1) HK1142547A1 (US20090233946A1-20090917-C00069.png)
IL (1) IL203258A (US20090233946A1-20090917-C00069.png)
PL (1) PL2175859T3 (US20090233946A1-20090917-C00069.png)
PT (1) PT2175859E (US20090233946A1-20090917-C00069.png)
WO (1) WO2009009740A1 (US20090233946A1-20090917-C00069.png)
ZA (1) ZA201000212B (US20090233946A1-20090917-C00069.png)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884110B2 (en) 2007-07-12 2011-02-08 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
WO2015084869A1 (en) 2013-12-02 2015-06-11 Allergan, Inc. Benzothiophene sulfonamides derivatives as chemokine receptor modulators
EP3050574A1 (en) 2015-01-28 2016-08-03 Universite De Bordeaux New compositions and methods of treating and/or preventing chronic obstructive pulmonary disease
US9670190B2 (en) 2013-03-12 2017-06-06 Allergan, Inc. Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators
WO2017210526A1 (en) 2016-06-03 2017-12-07 Chemocentryx, Inc. Method of treating liver fibrosis
WO2017218544A1 (en) 2016-06-13 2017-12-21 Chemocentryx, Inc. Methods of treating pancreatic cancer
WO2018098353A1 (en) 2016-11-23 2018-05-31 Chemocentryx, Inc. Method of treating focal segmental glomerulosclerosis
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US10758540B2 (en) 2017-10-11 2020-09-01 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
US10786494B2 (en) 2013-12-02 2020-09-29 Chemocentryx, Inc. CCR6 compounds
WO2021007386A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4252629A2 (en) 2016-12-07 2023-10-04 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
BR112013015260B1 (pt) 2010-12-16 2020-03-24 Allergan, Inc. Derivados de enxofre como moduladores de receptor de quimiocina, composição compreendendo o mesmo e seu uso
HUE038700T2 (hu) 2012-03-01 2018-11-28 Allergan Inc Benzofuran-2-szulfonamid származékok, mint kemokinreceptor-modulációk
CN104860950A (zh) * 2014-02-24 2015-08-26 重庆医药工业研究院有限责任公司 一种制备4-氯吡咯[2,3-d]并嘧啶的方法
CN111712242B (zh) 2017-09-25 2023-11-24 凯莫森特里克斯股份有限公司 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗
WO2019136368A2 (en) 2018-01-08 2019-07-11 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
US20190269664A1 (en) * 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
JP7007950B2 (ja) 2018-03-05 2022-01-25 東洋鋼鈑株式会社 パール調光沢フィルム
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES
AU2021267373A1 (en) 2020-05-06 2022-12-08 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1994020142A1 (en) 1993-03-12 1994-09-15 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US6451339B2 (en) 1999-02-26 2002-09-17 Lipocine, Inc. Compositions and methods for improved delivery of hydrophobic agents
WO2002101350A2 (en) 2001-06-07 2002-12-19 Chemocentryx Cell migration assay
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US20040023286A1 (en) 2001-06-07 2004-02-05 Chemocentryx. Method for multiple chemokine receptor screening for antagonists using RAM assay
WO2004046092A2 (en) 2002-11-18 2004-06-03 Chemocentryx Aryl sulfonamides
WO2005004810A2 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
WO2006076644A2 (en) 2005-01-14 2006-07-20 Chemocentryx, Inc. Heteroaryl sulfonamides and ccr2
US20070037794A1 (en) 2005-01-14 2007-02-15 Solomon Ungashe Heteroaryl sulfonamides and CCR2
WO2008008374A2 (en) 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
US9715915B2 (en) 2014-10-30 2017-07-25 Samsung Electronics Co., Ltd. Magneto-resistive devices including a free layer having different magnetic properties during operations

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3901855A (en) 1974-08-07 1975-08-26 Us Air Force Preparation of polybenzimidazoles
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4227437A (en) 1977-10-11 1980-10-14 Inloes Thomas L Frequency detecting apparatus
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4403607A (en) 1980-05-09 1983-09-13 The Regents Of The University Of California Compatible internal bone fixation plate
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
JPS61113060A (ja) 1984-11-08 1986-05-30 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
DE3825041A1 (de) 1988-07-20 1990-02-15 Schering Ag Pyrido(3,2-e)(1,2,4)triazolo(1,5-a)pyrimidin- 2-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, pflanzenwachstumsregulierender und fungizider wirkung
JPH04364168A (ja) 1990-08-08 1992-12-16 Taisho Pharmaceut Co Ltd スルホンアミドピリジン化合物
EP0472053B1 (en) 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
JPH06135934A (ja) 1991-12-27 1994-05-17 Ishihara Sangyo Kaisha Ltd ピリジン誘導体又はその塩を含有するホスホリパーゼ▲ａ２▼阻害剤、抗炎症剤又は抗膵炎剤
JPH06145145A (ja) 1991-12-27 1994-05-24 Ishihara Sangyo Kaisha Ltd アミノトリフルオロメチルピリジン誘導体又はその塩、それらの製造方法及びそれらを含有するホスホリパーゼａ▲２▼阻害剤、抗炎症剤並びに抗膵炎剤
US6159686A (en) 1992-09-14 2000-12-12 Sri International Up-converting reporters for biological and other assays
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
CA2244785C (en) 1996-02-22 2003-12-02 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
US5780488A (en) 1996-04-03 1998-07-14 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE360689T1 (de) 1996-09-10 2007-05-15 Kocher Theodor Inst Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
AR015104A1 (es) 1996-11-13 2001-04-18 Dowelanco Compuestos de n-arilsulfilimina sustituidos, utiles como catalizadores en la preparacion de compuestos de n-arilarilsulfonamida; proceso para preparar dichos compuestos y su uso para catalizar dicha preparacion.
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
US6251303B1 (en) 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6380206B1 (en) 1998-11-23 2002-04-30 Cell Pathways, Inc. Method of inhibiting neoplastic cells with 4,5-diaminopyrimidine derivatives
JP2000159665A (ja) 1998-11-27 2000-06-13 Nippon Kayaku Co Ltd リウマチの予防または治療剤
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
DE60013836T2 (de) 1999-06-28 2006-01-19 Janssen Pharmaceutica N.V. Replikationsinhibitoren des respiratorischen synzytialvirus
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
WO2001060369A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2001335714A (ja) 2000-03-22 2001-12-04 Fuji Photo Film Co Ltd アゾ色素、その製造方法、インクジェット用インク、インクジェット記録方法
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
JP2004501913A (ja) 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー ヘテロアリール−フェニル置換Ｘａ因子阻害剤
JP3699910B2 (ja) 2000-10-31 2005-09-28 株式会社東芝 データ伝送装置、データ伝送方法及びプログラム
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
WO2003051870A1 (en) 2001-12-18 2003-06-26 Astrazeneca Ab Novel compounds
US7119112B2 (en) 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US7101883B2 (en) 2002-03-18 2006-09-05 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases
EP1509477B1 (de) 2002-05-28 2007-05-02 Schott AG Vorrichtung zum blankpressen von glaskörpern
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US20070021466A1 (en) 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US20060111351A1 (en) 2002-11-18 2006-05-25 Solomon Ungashe Aryl sulfonamides
AU2003299797A1 (en) 2002-12-19 2004-07-14 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
NZ541234A (en) 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
AU2003290346A1 (en) 2002-12-24 2004-07-22 Biofocus Plc Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
EP1644008B1 (en) 2003-05-29 2011-12-21 Abbott Laboratories Continuous dosing regimen with abt-751
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
WO2007014008A2 (en) 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2007014054A2 (en) 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2008008394A1 (en) 2006-07-12 2008-01-17 Transform Pharmaceuticals, Inc. Tizanidine succinate salt forms and methods of making and using the same
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
WO2009009740A1 (en) * 2007-07-12 2009-01-15 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation
US10251888B2 (en) * 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1994020142A1 (en) 1993-03-12 1994-09-15 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US6451339B2 (en) 1999-02-26 2002-09-17 Lipocine, Inc. Compositions and methods for improved delivery of hydrophobic agents
WO2002101350A2 (en) 2001-06-07 2002-12-19 Chemocentryx Cell migration assay
US20040023286A1 (en) 2001-06-07 2004-02-05 Chemocentryx. Method for multiple chemokine receptor screening for antagonists using RAM assay
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
WO2004046092A2 (en) 2002-11-18 2004-06-03 Chemocentryx Aryl sulfonamides
US20040171654A1 (en) * 2002-11-18 2004-09-02 Solomon Ugashe Aryl sulfonamides
US6939885B2 (en) 2002-11-18 2005-09-06 Chemocentryx Aryl sulfonamides
WO2005004810A2 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
WO2006076644A2 (en) 2005-01-14 2006-07-20 Chemocentryx, Inc. Heteroaryl sulfonamides and ccr2
US20070037794A1 (en) 2005-01-14 2007-02-15 Solomon Ungashe Heteroaryl sulfonamides and CCR2
WO2008008374A2 (en) 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
US9715915B2 (en) 2014-10-30 2017-07-25 Samsung Electronics Co., Ltd. Magneto-resistive devices including a free layer having different magnetic properties during operations

Non-Patent Citations (42)

* Cited by examiner, † Cited by third party
Title
AMANN ET AL., DIABETES CARE, vol. 26, 2003, pages 2421 - 5
BERMAN ET AL., IMMUNOL. INVEST., vol. 17, 1988, pages 625 - 677
BIANCO JJ ET AL., ENDOCRINOLOGY, 2006, pages 2458
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 344, no. 3, 2006, pages 780 - 5
BIOORG. MED. CHEM. LETT., 2004, pages 3165 - 3168
BROEK ET AL., BR. J. CANCER, vol. 88, no. 6, 2003, pages 855 - 62
CHRISTIANSEN T ET AL., INT J OBES (LOND, vol. 29, no. 1, January 2005 (2005-01-01), pages 146 - 50
DAHINDEN ET AL., J. EXP. MED., vol. 179, 1994, pages 751 - 756
DAI ET AL., CHIN. MED. J. (ENGL, vol. 114, 2001, pages 864 - 8
DELEURAN ET AL., J. DERMATOL. SCI., vol. 13, no. 3, 1996, pages 228 - 36
DIAMOND ET AL., AM. J. PHYSIOL., vol. 266, 1994, pages F926 - 33
EDDY, GIACHELLI, KIDNEY INT., vol. 47, 1995, pages 1546 - 57
GILLITZER ET AL., J. INVEST. DERMATOL., vol. 101, no. 2, 1993, pages 127 - 31
GONG ET AL., J. EXP. MED., vol. 186, 1997, pages 131 - 7
GONZALEZ-CUADRADO ET AL., CLIN. EXP. IMMUNOL, vol. 106, 1996, pages 518 - 22
KAVANAUGH ET AL., J. IMMUNOF., vol. 146, 1991, pages 4149 - 4156
KITAGAWA ET AL., AM. J. PATHOL., vol. 165, 2004, pages 237 - 46
LLOYD ET AL., J. EXP. MED., vol. 185, 1997, pages 1371 - 80
MORII ET AL., J. DIABETES COMPLICATIONS, vol. 17, 2003, pages 11 - 5
NEOTE, CELL, vol. 72, 1993, pages 415 - 425
OGATA ET AL., J. PATHOL., vol. 182, 1997, pages 106 - 14
PLATER-ZYBERK ET AL., IMMUNOL. LETT., vol. 57, 1997, pages 117 - 20
SARTIPY ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 100, 2003, pages 7265 - 70
SARTIPY P, LOSKUTOFF DJ., PROC. NATL. ACAD. SCI. U.S.A., vol. 100, 2003, pages 7265
SCAIFE ET AL., RHEUMATOLOGY (OXFORD, vol. 43, 2004, pages 1346 - 52
SEGERER ET AL., J. AM. SOC. NEPHROL., vol. 11, 2000, pages 152 - 76
SHADIDI ET AL., SCAND. J. IMMUNOL., vol. 57, 2003, pages 192 - 8
SHIMIZU ET AL., J. AM. SOC. NEPHROL., vol. 14, 2003, pages 1496 - 505
STEPHAN ET AL., J. UROL., vol. 167, 2002, pages 1497 - 502
TAKAHASHI K ET AL., J. BIOL. CHEM., 2003, pages 46654
TAYLOR ET AL., ARTHRITIS RHEUM., vol. 43, 2000, pages 38 - 47
TUCCI ET AL., BIOMED. SCI. INSTRUM., vol. 34, 1997, pages 169 - 74
UENO ET AL., CLIN. CANCER RES., vol. 6, no. 8, 2001, pages 3282 - 9
VAN RIPER ET AL., J. EXP. MED., vol. 177, 1993, pages 851 - 856
VERVOORDELDONK ET AL., CURR. RHEUMATOL. REP., vol. 4, 2002, pages 208 - 17
VESTERGAARD ET AL., ACTA. DERM. VENEREOL., vol. 84, no. 5, 2004, pages 353 - 8
VILLIGER ET AL., J. IMMUNOL., vol. 149, 1992, pages 722 - 7
WADA ET AL., AM. J. PATHOL., vol. 165, 2004, pages 237 - 46
WEISBERG ET AL., J. CLIN. INVEST., vol. 112, 2003, pages 1796 - 808
WEISBERG SP ET AL., J. CLIN. INVEST, 2006, pages 115
XU H ET AL., J CLIN INVEST., vol. 112, no. 12, December 2003 (2003-12-01), pages 1821 - 30
YANG ET AL., ZHONGHUA YI XUE ZA ZHI, vol. 81, 2001, pages 73 - 7

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10899765B2 (en) 2007-07-12 2021-01-26 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US8546408B2 (en) 2007-07-12 2013-10-01 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US9394307B2 (en) 2007-07-12 2016-07-19 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US9745312B2 (en) 2007-07-12 2017-08-29 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US10208050B2 (en) 2007-07-12 2019-02-19 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US7884110B2 (en) 2007-07-12 2011-02-08 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US9670190B2 (en) 2013-03-12 2017-06-06 Allergan, Inc. Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators
WO2015084869A1 (en) 2013-12-02 2015-06-11 Allergan, Inc. Benzothiophene sulfonamides derivatives as chemokine receptor modulators
US10786494B2 (en) 2013-12-02 2020-09-29 Chemocentryx, Inc. CCR6 compounds
EP3050574A1 (en) 2015-01-28 2016-08-03 Universite De Bordeaux New compositions and methods of treating and/or preventing chronic obstructive pulmonary disease
EP3613435A1 (en) 2015-01-28 2020-02-26 Universite De Bordeaux Chemokine receptor cxcr4 inhibitors for treating and/or preventing chronic obstructive pulmonary disease
AU2017274521B2 (en) * 2016-06-03 2021-08-19 Chemocentryx, Inc. Method of treating liver fibrosis
US11357760B2 (en) 2016-06-03 2022-06-14 Chemocentryx, Inc. Method of treating liver fibrosis
WO2017210526A1 (en) 2016-06-03 2017-12-07 Chemocentryx, Inc. Method of treating liver fibrosis
RU2740902C2 (ru) * 2016-06-03 2021-01-21 Хемоцентрикс, Инк. Способ лечения фиброза печени
EP3463350A4 (en) * 2016-06-03 2020-01-29 ChemoCentryx, Inc. METHOD OF TREATING HEPATIC FIBROSIS
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
US10583131B2 (en) 2016-06-13 2020-03-10 Chemocentryx, Inc. Methods of treating pancreatic cancer
US11890276B2 (en) 2016-06-13 2024-02-06 Chemocentryx, Inc. Methods of treating pancreatic cancer
RU2768479C2 (ru) * 2016-06-13 2022-03-24 Хемоцентрикс, Инк. Способы лечения рака поджелудочной железы
US11116756B2 (en) 2016-06-13 2021-09-14 Chemocentryx, Inc. Methods of treating pancreatic cancer
IL263508B2 (en) * 2016-06-13 2023-06-01 Chemocentryx Inc Pancreatic cancer treatment methods
WO2017218544A1 (en) 2016-06-13 2017-12-21 Chemocentryx, Inc. Methods of treating pancreatic cancer
EP3468548A4 (en) * 2016-06-13 2020-01-22 ChemoCentryx, Inc. METHOD FOR THE TREATMENT OF LATIVAL CANCER
US10398685B2 (en) 2016-06-13 2019-09-03 Chemocentryx, Inc. Methods of treating pancreatic cancer
EP4134080A1 (en) * 2016-11-23 2023-02-15 ChemoCentryx, Inc. Ccr2 inhibitors for use in treating renal diseases
US11324736B2 (en) 2016-11-23 2022-05-10 Chemocentryx, Inc. Method of Treating Focal Segmental Glomerulosclerosis
US10973809B2 (en) 2016-11-23 2021-04-13 Chemocentryx, Inc. Method of treating focal segmental glomerulosclerosis
IL266751B (en) * 2016-11-23 2022-07-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
EP3544602A4 (en) * 2016-11-23 2020-07-08 ChemoCentryx, Inc. METHOD FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS
WO2018098353A1 (en) 2016-11-23 2018-05-31 Chemocentryx, Inc. Method of treating focal segmental glomerulosclerosis
IL294410B1 (en) * 2016-11-23 2023-10-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
RU2765737C2 (ru) * 2016-11-23 2022-02-02 Хемоцентрикс, Инк. Способ лечения фокально-сегментарного гломерулосклероза
EP4252629A2 (en) 2016-12-07 2023-10-04 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10980739B2 (en) 2016-12-14 2021-04-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10758540B2 (en) 2017-10-11 2020-09-01 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
EP3694504A4 (en) * 2017-10-11 2021-07-14 ChemoCentryx, Inc. TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CRC2 ANTAGONISTS
US11382915B2 (en) 2017-10-11 2022-07-12 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021007386A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Also Published As

Publication number Publication date
BRPI0813695A2 (pt) 2014-12-30
KR20180039765A (ko) 2018-04-18
KR101849560B1 (ko) 2018-04-17
DK2175859T3 (da) 2012-06-18
ATE548039T1 (de) 2012-03-15
PT2175859E (pt) 2012-06-06
CN101820881A (zh) 2010-09-01
US20170334920A1 (en) 2017-11-23
AU2008275000B2 (en) 2013-02-07
US10208050B2 (en) 2019-02-19
KR20170120711A (ko) 2017-10-31
US20170022205A1 (en) 2017-01-26
BRPI0813695B8 (pt) 2021-05-25
IL203258A (en) 2013-09-30
US8546408B2 (en) 2013-10-01
US20190169197A1 (en) 2019-06-06
CA2692761C (en) 2013-04-30
JP2010533203A (ja) 2010-10-21
EP2175859B1 (en) 2012-03-07
US20090233946A1 (en) 2009-09-17
US9394307B2 (en) 2016-07-19
CA2692761A1 (en) 2009-01-15
JP5306344B2 (ja) 2013-10-02
AU2008275000A1 (en) 2009-01-15
EP2175859A1 (en) 2010-04-21
KR101617050B1 (ko) 2016-05-02
ZA201000212B (en) 2011-04-28
HK1142547A1 (en) 2010-12-10
US7884110B2 (en) 2011-02-08
KR101790908B1 (ko) 2017-10-26
US20110319433A1 (en) 2011-12-29
ES2383568T3 (es) 2012-06-22
KR20160052766A (ko) 2016-05-12
CN101820881B (zh) 2013-05-01
US20140100237A1 (en) 2014-04-10
KR20100050499A (ko) 2010-05-13
PL2175859T3 (pl) 2012-09-28
BRPI0813695B1 (pt) 2019-02-12
KR101969689B1 (ko) 2019-04-16
US10899765B2 (en) 2021-01-26
US9745312B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
US10899765B2 (en) Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
JP6322325B2 (ja) Ｃｃ９アンタゴニストとしてのピラゾール−１−イルベンゼンスルホンアミド
EP2049515B1 (en) Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis
KR101433392B1 (ko) 트리아졸릴 페닐 벤젠설폰아마이드
EP2354126A1 (en) Heteroaryl sulfonamides and CCR2
KR20090091350A (ko) 단백질 키나제 억제제로 유용한 ５-시아노-４-피롤로[２,３ｂ]피리딘-３-일)-피리디민 유도체

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880107771.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08781709

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2692761

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008275000

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 203/CHENP/2010

Country of ref document: IN

Ref document number: MX/A/2010/000407

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 203258

Country of ref document: IL

Ref document number: 2010516274

Country of ref document: JP

Ref document number: 2008781709

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008275000

Country of ref document: AU

Date of ref document: 20080711

Kind code of ref document: A

Ref document number: 20107002541

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0813695

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100112